Johnson & Johnson (JNJ) — closed signal from December 11, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 11, 2026.
Predicted vs. what happened
What happened
Reached its target in 53 days.
The thesis — published December 11, 2025
Johnson & Johnson is a steady, defensive healthcare stock likely better for stability and income than for fast gains. Recent FDA recognition for a multiple myeloma drug combo and a higher analyst price target support longer term growth in oncology, but ongoing legal cases and other drug trial risks limit how much I expect the stock to rise over three months.
Primary drivers
- Above average composite score shows JNJ is a core defensive healthcare pick.
- Calm, orderly price behavior suggests buying on weakness rather than chasing gains.
- FDA Breakthrough tag for the drug combo makes the oncology outlook stronger.
- Analyst target lift helps the upside but legal and pipeline risks limit returns.
How it played out
JNJ: target reached in 53 days
Lyra published JNJ on 2025-12-11 at $209.16 with expected growth of 10% over a short-term window. The thesis was cautious but positive. It pointed to defensive healthcare quality, calm price behavior, FDA Breakthrough recognition for a multiple myeloma drug combo, and a higher analyst target. It also said legal cases and drug trial risks limited the expected rise.
Inside the window, JNJ reached the $230.08 target in 53 days. The peak was $251.71 on 2026-03-02, a 20.3% gain. It ended the window at $242.99. The published thesis played out, and the move went beyond the expected growth.
What happened during the window
On 2026-01-21, Johnson & Johnson reported fourth-quarter results, including $24.56 billion in sales and adjusted earnings of $2.46 a share. It also gave a 2026 outlook of $100.5 billion in sales and $11.53 in adjusted earnings per share. These were reported events, not stated causes of the stock move.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.